To serve as the institutional review board (IRB) of record for select niaid studies at US domestic sites.
Active Awarded Last action
- Contract number
- 75N93024F00002
- Awardee
-
Advarra, Inc. UEI GEGFK6SM8RM3
- Awarding agency
-
National Institute of Allergy and Infectious Diseases
National Institutes of Health, Department of Health and Human Services
- Obligated
- $163,718
Award facts
- Contract value 16% obligated
-
- $466,858.00 Current, with exercised options
- $995,037.00 Potential, with all options
- Completion date 45% complete
- Current and potential, with all options
- NAICS code
- 541715 Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
- PSC
- R499 Support- Professional: Other
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Columbia, MD 21044, USA
- Legislative mandates
-
- Service Contract Inventory FAR subpart 4.17
Award details come from SAM.gov/FPDS.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Exercise an Option | $81,859 | |
| Exercise an Option | $221,281 | |
| Exercise an Option | $81,859 | |
| Original award | $81,859 |
About this award
Advarra, Inc., doing business as Chesapeake IRB, has been awarded a delivery order valued at $995,037 by the National Institute of Allergy and Infectious Diseases (NIAID) to serve as the Institutional Review Board (IRB) of record for select NIAID studies at U.S. domestic sites. The firm fixed-price contract, awarded on April 1, 2024, will extend through December 31, 2029, with performance to be conducted in Columbia, Maryland. This delivery order was issued without a set-aside designation, meaning Advarra competed for the award in the open market. Advarra is a specialized provider of IRB services with extensive experience supporting federal agencies, particularly within the Department of Health and Human Services, offering protocol review, study oversight, and human subjects protection compliance services.
This delivery order falls under Advarra's larger Indefinite Delivery Contract (IDC) with NIAID, established on April 1, 2024, with a ceiling value of $13.999 million and performance through March 31, 2031. The parent IDC represents a significant long-term commitment from NIAID to leverage Advarra's expertise in managing complex, multi-site clinical research activities and ensuring federal compliance with human subjects protection regulations. Advarra's IRB services are critical to NIAID's mission of conducting ethical, federally compliant research on infectious diseases and allergies, supporting the agency's broader research portfolio across multiple therapeutic areas and study protocols.
Quick answers
Who was awarded contract 75N93024F00002?
75N93024F00002 was awarded to Advarra, Inc. by National Institute of Allergy and Infectious Diseases (National Institutes of Health) on April 1, 2024.
How much is contract 75N93024F00002 worth?
The government has obligated $163,718 on 75N93024F00002. Its current value, with exercised options, is $466,858. Its potential value, with all options, is $995,037.
Is contract 75N93024F00002 an order under another contract?
Yes. 75N93024F00002 is a delivery order under 75N93024D00002, an indefinite delivery contract.
Was contract 75N93024F00002 competed?
The extent of competition for 75N93024F00002 was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award